Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444102 | 0.95 | MTNR1A (0.43) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12515465 | 0.95 | MTNR1A (0.43) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19445539 | 0.92 | MTNR1A (0.41) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12515350 | 0.91 | MAPK14 (0.41) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10268065 | 0.91 | MAPK14 (0.41) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13351617 | 0.91 | HTT (0.40) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19445567 | 0.91 | MTNR1A (0.41) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16284392 | 0.89 | MTNR1A (0.39) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11947670 | 0.89 | MTNR1A (0.39) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21864682 | 0.89 | MTNR1A (0.39) | MTNR1AMTNR1BHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110178104-A1 | Anti-Heparin Compounds | POLYMEDIX INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178104-A1 | Anti-Heparin Compounds | POLYMEDIX INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084970-A1 | ANTI-HEPARIN COMPOUNDS | POLYMEDIX INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MTNR1A 49/4885MTNR1B 79/4885HTT 4522/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | MTNR1A 49/4885MTNR1B 79/4885HTT 4522/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MTNR1A 49/4885MTNR1B 79/4885HTT 4522/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | MTNR1A 748/4885MTNR1B 699/4885HTT 3818/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | MTNR1A 748/4885MTNR1B 699/4885HTT 3818/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | MTNR1A 129/4885MTNR1B 275/4885HTT 4281/4885 |
| US-20110178104-A1 | Anti-Heparin Compounds | SERPINC1, CFH, SERPINH1 | MTNR1A 2456/4885MTNR1B 2125/4885HTT 564/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | MTNR1A 49/4885MTNR1B 79/4885HTT 4522/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | MTNR1A 129/4885MTNR1B 275/4885HTT 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.